Advertisement

Supportive Care in Cancer

, Volume 26, Issue 1, pp 203–211 | Cite as

A prospective study of docetaxel-associated pain syndrome

  • Nicholas Chiu
  • Liying Zhang
  • Rebecca Dent
  • Angie Giotis
  • Jenna van Draanen
  • Daniela Gallo-Hershberg
  • Leonard Chiu
  • Ronald Chow
  • Bo Angela Wan
  • Mark Pasetka
  • Jordan Stinson
  • Erica Stacey
  • Sunil Verma
  • Henry Lam
  • Edward ChowEmail author
  • Carlo DeAngelis
Original Article

Abstract

Purpose

To investigate the natural history of taxane-associated acute pain syndrome (TAPS) in a docetaxel patient cohort and to examine the long-term manifestation of TAPS.

Patients and methods

For three consecutive treatment cycles, taxane-naive breast cancer patients completed diaries on days 1–7, 14, and 21 and telephone questionnaires 1, 3, 6, 9, and 12 months following treatment. Questionnaires to assess pain and interference were adapted from the Brief Pain Inventory. To examine the experience of arthralgia and myalgia as one syndrome, information on patient experiences with arthralgia or myalgia was elicited separately in order to determine how closely experiences of each toxicity correlated with each other. A ≥2 point increase from baseline was defined as an arthralgia or myalgia “pain flare,” and only those with “flare” were included in calculations of incidence.

Results

A total of 278 patients were accrued. Thirty-eight patients were omitted due to missing information, and 24 patients were omitted due to metastatic disease, for a total of 216 patients overall and 188 in the docetaxel cohort. A total of 74.5% of docetaxel patients experienced joint pain flare, and 78.2% experienced muscle pain flare at some point in the overall course of three treatment cycles. Joint and muscle pain peaked on days 4–5 for each cycle, and median pain severity for both joint and muscle pain was 4/10 during the 21-day period. Median onset of joint pain flare was 3 days for cycle 1 and 4 days for cycles 2 and 3, with an average median duration of 4 days. Median onset of muscle pain flare was 4 days for all three cycles, with a median duration of 4 days for cycles 1 and 2, and 5 days for cycle 3. Both joint and muscle pain persisted 1 year after treatment in approximately half of responding patients.

Conclusion

This study documents the significant incidence of TAPS in patients treated with docetaxel chemotherapy and shows a long-term persistence of the syndrome.

Keywords

Breast cancer Taxane Docetaxel Arthralgia Myalgia Taxane-associated pain syndrome 

Notes

Acknowledgements

Dr. Carlo DeAngelis is the senior author and principal investigator of this study. We thank the generous support of Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

520_2017_3836_MOESM1_ESM.docx (288 kb)
Appendix 1 (DOCX 288 kb)
520_2017_3836_MOESM2_ESM.docx (299 kb)
Appendix 2 (DOCX 298 kb)
520_2017_3836_MOESM3_ESM.docx (20 kb)
Appendix 3 (DOCX 20 kb)

References

  1. 1.
    Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803CrossRefGoogle Scholar
  2. 2.
    Conlin AK, Seidman AD (2007) Taxanes in breast cancer: an update. Curr Oncol Rep 9:22–30CrossRefGoogle Scholar
  3. 3.
    Ferguson T, Wilcken N, Vagg R et al (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 4:CD004421Google Scholar
  4. 4.
    Friedrich M, Diesing D, Villena-Heinsen C et al (2004) Taxanes in the first-line chemotherapy of metastatic breast cancer: review. Eur J Gynaecol Oncol 25:66–70PubMedGoogle Scholar
  5. 5.
    Garcia M, Jemal A, Ward EM et al (2007) Global cancer facts and figures 2007. Atlanta, GA, American Cancer SocietyGoogle Scholar
  6. 6.
    Cortes J, Saura C (2010) Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur J Cancer Suppl 8:1–10CrossRefGoogle Scholar
  7. 7.
    Markman M (2003) Prevention of paclitaxel-associated arthralgia and myalgia. J Support Oncol 1:233–234PubMedGoogle Scholar
  8. 8.
    Fernandes R., Mazzarello S, Majeed H, et al. 2015Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review. Support Care Cancer: 1-12Google Scholar
  9. 9.
    Loprinzi CL, Reeves BN, Dakhil SR et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478CrossRefGoogle Scholar
  10. 10.
    Loprinzi CL, Maddocks-Christianson K, Wolf SL et al (2007) The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 13:399–403CrossRefGoogle Scholar
  11. 11.
    Reeves BN, Dakhil SR, Sloan JA et al (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy. Cancer 118:5171–5178CrossRefGoogle Scholar
  12. 12.
    Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664–5671CrossRefGoogle Scholar
  13. 13.
    Chiu N, Zhang L, Gallo-Hershberg D, Dent R, Chiu L, Pasetka M, van Draanen J, Chow R, Lam H, Verma S, Stinson J (2016) Which pain intensity scale from the brief pain inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia? Support Care Cancer 24:2979–2988CrossRefGoogle Scholar
  14. 14.
    Drug Product Database Online Query [Internet]. Ottawa (ON): Government of Canada; c2017 [updated 2017 Feb 17; cited 2017]. Paclitaxel for injection [product monograph] Available from: https://pdf.hres.ca/dpd_pm/00009873.PDF
  15. 15.
    Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M, Chow E, DeAngelis C (2017) Taxane-induced arthralgia and myalgia: a literature review. J Oncol Pharm Pract 23:56–67CrossRefGoogle Scholar
  16. 16.
    Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, Jacobs C, Ong M, Clemons M (2016) Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review. Support Care Cancer May 5:1–8Google Scholar
  17. 17.
    Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94–102CrossRefGoogle Scholar
  18. 18.
    Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17CrossRefGoogle Scholar
  19. 19.
    Hilkens PHE, Verweij J, Stoter G, Vecht CJ, Van Putten WLJ, Van den Bent MJ (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46(1):104–108CrossRefGoogle Scholar
  20. 20.
    Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24(6):1443–1449CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Nicholas Chiu
    • 1
  • Liying Zhang
    • 1
  • Rebecca Dent
    • 2
  • Angie Giotis
    • 1
  • Jenna van Draanen
    • 1
  • Daniela Gallo-Hershberg
    • 3
    • 4
  • Leonard Chiu
    • 1
  • Ronald Chow
    • 1
  • Bo Angela Wan
    • 1
  • Mark Pasetka
    • 1
  • Jordan Stinson
    • 1
  • Erica Stacey
    • 1
  • Sunil Verma
    • 1
  • Henry Lam
    • 1
  • Edward Chow
    • 1
    • 5
    Email author
  • Carlo DeAngelis
    • 1
    • 4
  1. 1.Sunnybrook Odette Cancer CentreUniversity of TorontoTorontoCanada
  2. 2.National Cancer Centre, SingaporeSingaporeSingapore
  3. 3.North York General HospitalTorontoCanada
  4. 4.Leslie Dan Faculty of PharmacyUniversity of TorontoTorontoCanada
  5. 5.Department of Radiation OncologyOdette Cancer Centre, Sunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations